Jeito Capital is a global investment company that invests in companies in the field of medical innovation.
Business Model:
Revenue: $0
Employees: 0-0
Address: 6 boulevard Haussmann
City: Paris
State: île-de-france
Zip: 75001
Country: FR
Jeito Capital is a global investment company that invests in companies in the field of medical innovation. It focuses both on financing ground-breaking medical innovation and promoting positive societal impact. It empowers and supports entrepreneurs through its expert, integrated, multi-talented team. The company was founded in 2018 and is based in Paris with a presence in Europe and the United States.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2022 | Eyebiotech | Series A | 0 |
6/2021 | Alentis Therapeutics | Series B | 66.8M |
10/2020 | SparingVision | Venture Round | 0 |
12/2020 | Innoskel | Series A | 0 |
9/2022 | SparingVision | Series B | 0 |
4/2023 | Alentis Therapeutics | Series C | 0 |
10/2020 | SparingVision | Series A | 52.7M |
11/2022 | Human Immunology Biosciences | Series A | 0 |
3/2023 | Noema Pharma | Series B | 0 |
5/2021 | Pulmocide | Series C | 0 |
11/2022 | CatalYm | Series C | 0 |
4/2022 | CDR-Life AG | Series A | 0 |
9/2020 | Neogene Therapeutics | Series A | 110M |
11/2021 | Quell Therapeutics | Series B | 0 |
12/2022 | Pulmocide | Series C | 0 |
2/2022 | NMD Pharma | Venture Round | 0 |
3/2022 | Precirix | Series B | 0 |
4/2023 | Alentis Therapeutics | Series C | 0 |
3/2023 | Noema Pharma | Series B | 0 |
12/2022 | Pulmocide | Series C | 0 |
11/2022 | CatalYm | Series C | 0 |
11/2022 | Human Immunology Biosciences | Series A | 0 |
9/2022 | SparingVision | Series B | 0 |
4/2022 | CDR-Life AG | Series A | 0 |
3/2022 | Precirix | Series B | 0 |
2/2022 | Eyebiotech | Series A | 0 |
2/2022 | NMD Pharma | Venture Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|